A 35-year-old woman with SLE presents with severe thrombocytopenia (platelet count 15,000/μL), hemolytic anemia (Hb 7.2 g/dL, reticulocyte count 8%, LDH 680 U/L, negative direct Coombs test), and no clinical evidence of active lupus nephritis or vasculitis. She is seronegative for antiphospholipid antibodies. What is the drug of choice for initial treatment of SLE-associated thrombocytopenia and hemolytic anemia?

## First-Line Treatment of SLE-Associated Cytopenias (Thrombocytopenia & Hemolytic Anemia) **Key Point:** Corticosteroids are the first-line treatment for SLE-associated thrombocytopenia and hemolytic anemia because they suppress the production of pathogenic autoantibodies and reduce complement-mediated cell destruction. ### Pathophysiology In SLE, cytopenias result from: 1. **Immune complex deposition** on blood cell surfaces 2. **Complement activation** (C3b/C4b opsonization of RBCs and platelets) 3. **Autoantibody production** (anti-RBC, anti-platelet IgG) 4. **Phagocytosis** by splenic macrophages (hence the negative direct Coombs test in some SLE cases) **Clinical Pearl:** The negative direct Coombs test does NOT rule out SLE-associated hemolytic anemia; SLE hemolysis can occur via complement-mediated mechanisms (IgM antibodies, immune complexes) rather than IgG alone. ### Corticosteroid Dosing for Cytopenias | Severity | Initial Dose | Duration | |----------|--------------|----------| | **Mild** (Plt 30–50k, Hb > 8) | Prednisolone 0.5–1 mg/kg/day | 4–6 weeks, then taper | | **Moderate** (Plt 15–30k, Hb 7–8) | Prednisolone 1–1.5 mg/kg/day | 4–8 weeks, then taper | | **Severe** (Plt < 15k, Hb < 7) | IV methylprednisolone 1 g daily × 3 days, then oral prednisolone 1–1.5 mg/kg/day | Initial IV pulse, then oral taper | **High-Yield:** Response rates to corticosteroids are **80–90%** for SLE-associated thrombocytopenia and **70–80%** for hemolytic anemia, making them the undisputed first-line agent. ### When to Add Second-Line Agents ```mermaid flowchart TD A[SLE cytopenias]:::outcome --> B[Start corticosteroids]:::action B --> C{Response at 2-4 weeks?}:::decision C -->|Yes| D[Continue taper]:::action C -->|No| E[Add second-line agent]:::action E --> F{Platelet count < 10k or life-threatening bleeding?}:::decision F -->|Yes| G[IVIG or IV methylprednisolone pulse]:::action F -->|No| H[Azathioprine or MMF]:::action G --> I[Rituximab if refractory]:::action H --> I ``` ### Role of IVIG - **Indicated when:** Platelet count < 10,000/μL with bleeding risk, or corticosteroid failure - **Mechanism:** Blocks Fc receptors on splenic macrophages, reducing opsonized cell destruction - **Onset:** Rapid (24–48 hours), but effect is transient (2–4 weeks) - **NOT first-line** because it is expensive, requires IV access, and does not address underlying autoimmunity ### Role of Rituximab - **B cell–depleting monoclonal antibody** - **Reserved for:** Corticosteroid-refractory or IVIG-refractory cytopenias - **Response rate:** 60–70% in refractory SLE thrombocytopenia - **NOT first-line** due to cost, infection risk, and delayed onset (weeks to months) ### Why Splenectomy Is Not First-Line - **Historically used** before modern immunosuppression - **Current role:** Considered only in corticosteroid-dependent or refractory cases after medical therapy failure - **Contraindicated in:** Active SLE with systemic manifestations (risk of flare post-operatively) **Mnemonic:** **CRASH** — **C**orticosteroids, **R**ituximab, **A**zatioprine, **S**plenectomy, **H**igh-dose IVIG (in order of first-line to last-line for SLE cytopenias). [cite:Harrison 21e Ch 297]